Price | 1W % | 1M % | 3M % | 6M % | 1Y % | YTD % |
---|---|---|---|---|---|---|
-- | -- | -- | -- | -- | -- | -- |
AI Generated Qualitative Analysis
Your time is precious, so save it. Use AI to get the most important information from the business.
Learn about Evogene Ltd.
Evogene Ltd. News
Evogene Ltd. Quantitative Score
About Evogene Ltd.
Evogene Ltd., together with its subsidiaries, operates as a computational biology company. It focuses on product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through big data and artificial intelligence, designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules, and genetic elements. The company operates through three segments: Agriculture, Human Health, and Industrial Applications. The Agriculture segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance. Its products focus on various crops, such as corn, soybean, wheat, rice, and cotton. The Industrial Applications segment develops enhanced castor bean seeds to serve as a feedstock source for other industrial uses. The Human Health segment discovers and develops human microbiome-based therapeutics for the treatment of immuno-oncology, GI related disorders, and antimicrobial resistance organisms. The company also provides medical cannabis products. It operates in the United States, Israel, Brazil, and internationally. The company has strategic collaborations and licensing agreements with agricultural companies, such as BASF SE, Corteva, and Bayer; and through its subsidiary, Canonic Ltd., has a collaboration agreement with Cannbit Ltd. for the development of novel medical cannabis products. Evogene Ltd. was founded in 1999 and is headquartered in Rehovot, Israel.
Evogene Ltd. Earnings & Revenue
Evogene Ltd. Financials
Table Compare
Compare EVGN metrics with: | |||
---|---|---|---|
Earnings & Growth | EVGN | None | |
EPS (TTM) YoY Growth | -- | -- | |
Revenue (TTM) YoY Growth | -- | -- | |
Valuation (TTM) | EVGN | None | |
Price/Earnings Ratio | -- | -- | |
Price/Sales Ratio | -- | -- | |
Profitability & Efficiency (TTM) | EVGN | None | |
Net Profit Margin | -- | -- | |
Return on Equity | -- | -- | |
Financial Health (TTM) | EVGN | None | |
Debt/Assets Ratio | -- | -- | |
Assets/Liabilities Ratio | -- | -- | |
Evogene Ltd. Income
Evogene Ltd. Balance Sheet
Evogene Ltd. Cash Flow
Evogene Ltd. Financials Over Time
Analysts Rating
Strong Buy
Buy
Hold
Sell
Strong Sell
Metrics Scores
Metrics | Score |
---|---|
Discounted Cash Flows | Strong Sell |
Return on Equity | Strong Sell |
Return on Assets | Strong Sell |
Debt/Equity Ratio | Strong Sell |
Price/Earnings Ratio | Strong Sell |
Price/Book Ratio | Strong Sell |
Price Targets
Disclaimer: This 3rd party analysis information is for reference only and does not constitute investment advice.
Historical Market Cap
Shares Outstanding
Evogene Ltd. Executives
Name | Role |
---|---|
Mr. Ofer Haviv CPA | Chief Executive Officer & President |
Dr. Elran Hillel Haber M.B.A., Ph.D. | Chief Executive Officer of Biomica Ltd |
Dr. Brian Ember | Chief Executive Officer of AgPlenus Ltd |
Mr. Mark Kapel | Chief Technology Officer |
Mr. Sassi Masliah | Vice President of Corporate Development |
Name | Role | Gender | Date of Birth | Pay |
---|---|---|---|---|
Mr. Ofer Haviv CPA | Chief Executive Officer & President | Male | 1966 | 390K |
Dr. Elran Hillel Haber M.B.A., Ph.D. | Chief Executive Officer of Biomica Ltd | 1980 | 302K | |
Dr. Brian Ember | Chief Executive Officer of AgPlenus Ltd | 1976 | 287K | |
Mr. Mark Kapel | Chief Technology Officer | Male | 1977 | 276K |
Mr. Sassi Masliah | Vice President of Corporate Development | Male | 1979 | 245K |